The present study is a single-centre prospective study that will enrol pregnant women during their first trimester of pregnancy (11+0 - 13+6 weeks of gestation).
During pregnancy, women will undergo standard clinical evaluation and management. During the two study visits (enrollment and 24+0 - 27+6 weeks of gestation) the investigators will perform arterial tonometry (Pulsepen) and in vivo darkfield microscopy (Glycocheck) to evaluate endothelial and vascular function. A urine sample and a blood sample for specific study analyses on metabolic profile, endothelial and angiogenic markers will be collected. Pregnancy outcomes will be collected at delivery and five years after delivery all the participants will be interview to collect long-term cardiovascular outcomes. Serum endothelial and angiogenic markers will be evaluated only in participants who will develop hypertensive disorders of pregnancy and in an equal number of controls matched for age and body mass index at the time of conception.
Age greater than or equal to 18 years
Single pregnancy
No previous pregnancies lasting more than 12 weeks
Participant willing and able to give informed consent for participation in the study
Intermediate-high risk of genetic abnormalities and/or need to perform invasive tests (amniocentesis, villocentesis)
History of solid organ or hematopoietic stem cell transplantation
Chronic renal failure (eGFR≤45ml/min/1.73m2)
Chronic treatment with antihypertensive drugs and/or xanthine oxidase (XO) inhibitors
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Lead sponsor
University of Bologna
Collaborator